Alvotech (NASDAQ:ALVO) Stock Rated “Hold” by Wall Street Brokerages

Shares of Alvotech (NASDAQ:ALVO) have been assigned an average rating of “Hold” from the seven analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $8.40.

A number of brokerages have weighed in on ALVO. Jefferies Financial Group initiated coverage on shares of Alvotech in a report on Tuesday. They issued a “buy” rating and a $9.00 price target for the company. Zacks Research lowered shares of Alvotech from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Bank of America assumed coverage on shares of Alvotech in a research note on Monday, August 24th. They issued a “buy” rating and a $7.00 target price for the company. Barclays upgraded shares of Alvotech from an “underweight” rating to an “overweight” rating and increased their target price for the company from $4.00 to $8.00 in a research note on Wednesday, September 16th. Finally, Wall Street Zen downgraded Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th.

Institutional Trading of Alvotech

Several institutional investors have recently modified their holdings of ALVO. ProShare Advisors LLC acquired a new position in shares of Alvotech in the third quarter valued at $68,000. Commonwealth Equity Services LLC bought a new position in Alvotech in the third quarter worth $69,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Alvotech during the third quarter worth $100,000. China Universal Asset Management Co. Ltd. boosted its stake in Alvotech by 24.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 61,712 shares of the company’s stock worth $365,000 after buying an additional 12,049 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Alvotech by 146.9% in the 1st quarter. Renaissance Technologies LLC now owns 63,200 shares of the company’s stock valued at $217,000 after buying an additional 37,600 shares during the period.

Key Stories Impacting Alvotech

Investors following ALVO have been watching these stories:

• Positive Sentiment: Third-quarter product and service revenue rose 78% year over year to $58.2 million, and adjusted EBITDA more than doubled to $31.5 million. Alvotech financial results and business update
• Positive Sentiment: The FDA accepted Alvotech’s application for its proposed Entyvio biosimilar, while the company and partner Advanz submitted a proposed Eylea HD biosimilar application in Europe. FDA-approved production changes for Simlandi are expected to more than double output per batch and add manufacturing flexibility. Business update
• Negative Sentiment: Nine-month adjusted revenue fell 23% year over year to $323.4 million, gross margin narrowed to 54% from 59%, and cash declined to $61.5 million from $172.4 million at year-end 2025. The company maintained its 2026 revenue and EBITDA ranges but now expects results toward the lower end. Alvotech Q3 revenue falls

Alvotech Trading Up 0.8%

Shares of ALVO stock opened at $4.92 on Friday. Alvotech has a 12 month low of $2.94 and a 12 month high of $6.53. The stock has a 50 day moving average of $5.27 and a 200-day moving average of $4.21.

Alvotech (NASDAQ:ALVO) last posted its quarterly earnings data on Wednesday, November 11th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The business had revenue of $111.60 million during the quarter, compared to the consensus estimate of $125.20 million. As a group, sell-side analysts expect that Alvotech will post -0.01 EPS for the current fiscal year.

Alvotech Company Profile

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.